World Leaders in Protein Engineering to Convene in Boston from April 30 - May 4 for CHI’s Eighth Annual PEGS: the Essential Protein Engineering Summit

Share Article

More than 1,200 attendees to hear presentations on the latest in protein design, drug discovery, antibody engineering and more

Cambridge Healthtech Institute is proud to announce the production of its Eighth Annual PEGS: the essential protein engineering summit. This comprehensive event features 12 tracks, 13 short courses, a pre-conference partnering forum for showcasing early stage companies, more than 300 speakers, 80 exhibitors, 100 posters and 1,200 attendees. Topics span from early stage discovery of new methods for protein expression and antibody engineering, to improved analytical techniques, and clinical results in the most promising areas of biotechnology. There is tremendous momentum and investment in biologics, and the PEGS Summit offers an unparalleled view of the field.

DISCOVERY STREAM CONFERENCES

  • Phage and Yeast Display
  • Engineering Antibodies
  • Antibody Optimization

EXPRESSION STREAM CONFERENCES

  • Difficult to Express Proteins
  • Optimizing Protein Expression
  • Purifying Antibodies

ANALYTICAL STREAM CONFERENCES

  • Characterization of Biotherapeutics
  • Protein Aggregation and Stability
  • Immunogenicity

ANTIBODIES STREAM CONFERENCES

  • Antibodies for Cancer Therapy
  • Bispecific Antibodies
  • Antibody Drug Conjugates

KEYNOTE PRESENTERS INCLUDE
Steve J. Swanson, Ph.D., Executive Director, Medical Sciences, Clinical Immunology, Amgen, Inc.

Kurt A. Brorson, Ph.D., Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration

Amy Rosenberg, Director, Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration

Alain Beck, Ph.D., Associate Editor, mAbs; Head, Physico-Chemistry Department, Centre d’Immunologie Pierre Fabre (CIPF)

Ivor Royston, M.D., Managing Partner, Forward Ventures

William H. Brondyk, Ph.D., Senior Scientific Director, Therapeutic Protein Discovery, Genzyme – A Sanofi Company

David R. Liu, Ph.D., Professor of Chemistry and Chemical Biology, Howard Hughes Medical Institute Investigator, Harvard University

Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Pathology & LAR, MedImmune

David J. Roush, Ph.D., Senior Investigator, BioProcess, Protein Purification Development, Merck Research Labs

Ira H. Pastan, M.D., Chief, Molecular Biology, National Cancer institute, NIH

Anthony J. Coyle, Ph.D., Vice President & CSO, Centers for Therapeutic Innovation, Pfizer, Inc.

Gregory A. Weiss, Ph.D., Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine

John McCafferty, Ph.D., Research Director, Biochemistry, University of Cambridge

Thomas Laue, Ph.D., Professor, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire

Michael Gross, Ph.D., Professor, Chemistry & Immunology and Internal Medicine, Washington University

Advance registration rates are available until March 30, 2012. To view the program agenda and to register, please visit http://www.PEGSummit.com.

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. http://www.chicorporate.com

For more information:
Tracey Fielding
Cambridge Healthtech Institute
(781) 972-5429
tfielding(at)healthtech(dot)com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tracey Fielding
Cambridge Healthtech Institute
(781) 972-5429
Email >
Visit website